Predictors of mortality in patients infected with carbapenem-resistant Acinetobacter baumannii: A systematic review and meta-analysis
- PMID: 31003750
- DOI: 10.1016/j.ajic.2019.03.003
Predictors of mortality in patients infected with carbapenem-resistant Acinetobacter baumannii: A systematic review and meta-analysis
Abstract
Background: Carbapenem-resistant Acinetobacter baumannii (CRAB) tops the list of threats to human health. Studies exploring predictors of mortality in patients with CRAB infection produced conflicting results.
Methods: A systematic search of the PubMed, Embase, and the Cochrane Library databases was performed from inception to June 2018 to identify studies reporting mortality predictors in patients infected with CRAB. Two authors independently assessed trials for inclusion and data extraction.
Results: A total of 19 observational studies were enrolled in this study. Factors associated with mortality of patients infected with CRAB were inappropriate empirical antimicrobial treatment (odds ratio [OR], 5.04; 95% confidence interval [CI], 2.56-9.94), septic shock (OR, 5.65; 95% CI, 2.35-13.57), chronic liver disease (OR, 2.36; 95% CI, 1.33-4.16), chronic renal disease (OR, 2.02; 95% CI, 1.37-2.99), hypertension (OR, 1.74; 95% CI, 1.08-2.80), neutropenia (OR, 3.31; 95% CI, 1.25-8.77), immunosuppressant use (OR, 3.15; 95% CI, 1.94-5.11), total parenteral nutrition (OR, 1.66; 95% CI, 1.08-2.56), and intubation (OR, 5.03; 95% CI, 2.33-10.87). Acute Physiology and Chronic Health Evaluation II score at admission and Pitt bacteremia score at the onset of CRAB bacteremia were higher in nonsurvivors.
Conclusions: Our study suggests that severity of baseline condition and receiving inappropriate experience antibiotic therapy are major risk factors for higher mortality in patients with CRAB infections. These findings may help clinicians to take appropriate preventive measures and decrease mortality in such patients.
Keywords: Bloodstream infection; Carbapenem resistance; Nosocomial pneumonia; Risk factors.
Copyright © 2019 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia.J Microbiol Immunol Infect. 2012 Oct;45(5):356-62. doi: 10.1016/j.jmii.2011.12.009. Epub 2012 May 9. J Microbiol Immunol Infect. 2012. PMID: 22575430
-
A case-control study to identify predictors of 14-day mortality following carbapenem-resistant Acinetobacter baumannii bacteraemia.Clin Microbiol Infect. 2014 Dec;20(12):O1028-34. doi: 10.1111/1469-0691.12716. Epub 2014 Aug 11. Clin Microbiol Infect. 2014. PMID: 24930471
-
Changes in the early mortality of adult patients with carbapenem-resistant Acinetobacter baumannii bacteremia during 11 years at an academic medical center.J Infect Chemother. 2019 Jan;25(1):6-11. doi: 10.1016/j.jiac.2018.09.011. Epub 2018 Oct 19. J Infect Chemother. 2019. PMID: 30342838
-
Clinical efficacy and safety of polymyxins based versus non-polymyxins based therapies in the infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis.BMC Infect Dis. 2020 Apr 21;20(1):296. doi: 10.1186/s12879-020-05026-2. BMC Infect Dis. 2020. PMID: 32316926 Free PMC article.
-
Comparison of cefiderocol and colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review with meta-analysis and trial sequential analysis.BMC Infect Dis. 2024 Sep 13;24(1):967. doi: 10.1186/s12879-024-09899-5. BMC Infect Dis. 2024. PMID: 39271977 Free PMC article.
Cited by
-
Co-Administration of High-Dose Nebulized Colistin for Acinetobacter baumannii Bacteremic Ventilator-Associated Pneumonia: Impact on Outcomes.Antibiotics (Basel). 2024 Feb 8;13(2):169. doi: 10.3390/antibiotics13020169. Antibiotics (Basel). 2024. PMID: 38391555 Free PMC article.
-
Remdesivir, Renal Function and Short-Term Clinical Outcomes in Elderly COVID-19 Pneumonia Patients: A Single-Centre Study.Clin Interv Aging. 2021 Jun 3;16:1037-1046. doi: 10.2147/CIA.S313028. eCollection 2021. Clin Interv Aging. 2021. PMID: 34113086 Free PMC article.
-
Exploring Roles of the Polysaccharide Capsule in Pathogenesis of Hypervirulent Acinetobacter baumannii Clinical Isolate Lac-4.Antibiotics (Basel). 2023 Dec 20;13(1):10. doi: 10.3390/antibiotics13010010. Antibiotics (Basel). 2023. PMID: 38275320 Free PMC article.
-
Optimizing Treatment Strategies for Carbapenem-Resistant Acinetobacter Baumannii-Associated Pneumonia: A Multicenter Study in Chinese Hospitals.Infect Drug Resist. 2024 Oct 13;17:4403-4415. doi: 10.2147/IDR.S473088. eCollection 2024. Infect Drug Resist. 2024. PMID: 39421018 Free PMC article.
-
Transcriptomic analysis reveals the regulatory role of quorum sensing in the Acinetobacter baumannii ATCC 19606 via RNA-seq.BMC Microbiol. 2022 Aug 16;22(1):198. doi: 10.1186/s12866-022-02612-z. BMC Microbiol. 2022. PMID: 35971084 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical